$HIMS --- On June 2,
$HIMS officially announced it has completed the full acquisition of Australian digital health giant Eucalyptus — owner of leading weight management brand Juniper. The deal not only gives HIMS its first entry into Japan, Germany, Canada and Australia, but also immediately expands its subscriber base materially.
$HIMS has also struck a landmark GLP-1 strategic partnership with Novo Nordisk — an epic, game-changing catalyst.
This resolves the long-running legal and licensing disputes that had weighed heavily on the stock, and represents a decisive win for HIMS. The two companies have buried the hatchet: Novo Nordisk's FDA-approved blockbuster weight loss drugs (including Wegovy and Ozempic) will now be distributed directly on the HIMS platform. This instantly transforms HIMS from a controversial compounded medication provider operating on regulatory fringes into a legitimate, official partner of the world's largest weight loss drug maker.
On June 4, the company appointed Dr. Anant Vinjamoori as its new Chief Medical Officer, as it pushes into cutting-edge areas including longevity medicine and multi-cancer early detection (MCED). Meanwhile, its ongoing $250 million share repurchase program continues to provide strong downside support for the stock.
1. The Ultimate Subscription Model Solution for Digital Healthcare
Traditional healthcare is plagued by cumbersome processes and social stigma around sensitive conditions (hair loss, sexual health, mental health, obesity). HIMS hits the pain point of modern consumers head-on with highly personalized, frictionless online consultations and direct-to-door medication delivery.
Exceptional user stickiness: As of Q1 2026, active subscribers on the platform have surpassed 2.6 million (up 9% YoY).
High margins compounding flywheel: ~75% gross margins give it ample capital for marketing spend. As user retention improves, customer acquisition cost (CAC) steadily dilutes, unlocking dramatic operating leverage over time.
2. GLP-1 Weight Loss Drugs as the Second Growth Curve
Against a backdrop of global GLP-1 supply shortages, HIMS provides a critical, high-demand distribution channel. With the regulatory tailwind for compounded medications facing FDA re-evaluation risk, HIMS has pivoted nimbly: it now offers personalized non-GLP-1 oral weight loss formulations, and has locked in supply of legitimate branded injectables via its Novo Nordisk partnership — directly riding the largest weight loss drug boom in human history.
3. Global, Multi-Dimensional Consumer Health Ecosystem
By acquiring Eucalyptus, HIMS is replicating its U.S. success model globally while expanding into new verticals. What started as a niche men's health platform is now evolving into a comprehensive global consumer healthcare platform spanning full-body weight management, dermatology, early cancer screening and routine wellness, powered by partnerships with 10 leading health brands including Dexcom, MyFitnessPal and HelloFresh.